SEC Tracker
Get the app
AUPH · XBRL financial data

Aurinia Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (AUPH's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers45,09550,30357,19267,77159,86762,46570,00873,46877,11477,70583,22083,699
Cost of revenue5,395*7,7528,9096,0355,552*8,5747,1158,1778,799*6,5056,5558,306
Research and development10,228*5,5514,0803,0478,107*5,7437,4328,43510,895*7,47013,05016,613
Selling, general and administrativeyear only———————————
General and administrative50,072*47,69544,93442,36737,032*20,33926,01826,18229,255*22,02923,50824,684
Total operating expenses74,76963,55658,70556,02361,53640,61849,92543,72343,875———
Other operating income (expense)(9,074)*4,125290(4,574)4,506*(4,429)(9,246)(929)5,074*(279)6,2341,267
Operating income (loss)(29,674)(13,253)(1,513)11,748(1,669)21,84720,08329,74533,23941,42246,34135,363
Interest income4,568*4,5264,1894,2673,988*3,5693,1903,3163,498*3,5153,3934,219
Interest expense1,310*1,2831,1981,2081,146*1,0671,1171,0991,047*1,012948867
Income tax expense (benefit)459*739756457(256)*1,005643411(175,104)*9,57011,3727,012
Net income (loss)(26,875)(10,749)72214,3501,42923,34421,51331,551210,79434,35537,41431,703
Earnings per share, basic USD per share(0.19)(0.07)0.010.100.010.170.160.241.600.260.290.24
Earnings per share, diluted USD per share(0.19)(0.07)0.010.100.010.160.160.231.530.250.280.23
Weighted average shares, basic thousands of shares144,661*144,013143,327143,051141,850*138,917134,873131,808131,974*132,375130,081133,434
Weighted average shares, diluted thousands of shares144,661*144,013144,110145,651150,956*143,199137,526136,008138,152*137,639133,530135,173

Balance sheet

CSV

Fiscal quarters (AUPH's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents48,75563,91433,26536,63083,39666,11352,91472,88980,16040,749179,73245,792
Marketable securities301,614255,453297,068311,605275,043246,473262,131278,619317,784337,775263,291440,735
Inventory39,70539,76138,85338,71439,22846,19546,50344,79345,69046,41045,15143,728
Total current assets424,800398,223409,666440,459446,596405,762408,970438,737491,967480,244541,324587,886
Property and equipment, net3,3543,1983,0432,8872,7312,5762,4212,2662,1111,9861,8621,737
Right-of-use asset4,4984,3944,2884,1794,0683,9543,8373,7183,5961,6591,5181,372
Total assets548,062516,634523,529549,361550,645504,850502,562527,528751,587723,997792,262825,704
Accounts payable4,327———5,1874,2203,3122,2143,3132,6611,7353,014
Accrued liabilities50,062———64,97142,35349,70449,53666,62158,19664,11263,299
Total current liabilities77,18871,05276,90378,60997,76368,40678,26676,22093,72486,55699,89396,005
Lease liability, non-current6,5306,3396,1465,9515,7435,5385,3345,1194,9002,3182,0091,677
Total liabilities170,108157,158158,913161,359173,167154,660167,261161,757170,256156,371177,398168,185
Accumulated deficit(942,322)(953,071)(952,349)(937,999)(936,570)(913,226)(891,713)(860,162)(649,368)(615,013)(577,599)(545,896)
Total stockholders' equity377,954359,476364,616388,002377,478350,190335,301365,771581,331567,626614,864657,519
Total liabilities and equity548,062516,634523,529549,361550,645504,850502,562527,528751,587723,997792,262825,704
Common shares outstanding (cover page) thousands of shares144,618143,019142,991143,179137,339135,104131,630131,841132,971128,602133,051133,999

Cash flows

CSV

Fiscal quarters (AUPH's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(26,875)(10,749)72214,3501,42923,34421,51331,551210,79434,35537,41431,703
Stock-based compensation11,768*5,7378,586*8,327*8,946*(3,409)5,440*5,919*6,728*(866)2,839*6,124*
Depreciation and amortizationyear only4,8474,843*4,893*4,862*4,8564,864*4,865*4,864*4,8164,834*4,841*
Net cash from operating activities14,312*(18,598)15,843*17,029*30,114*1,30044,241*44,449*45,668*32,56052,566*46,367*
Net cash from investing activities(6,257)*49,233(38,622)*(10,572)*39,223*31,032(13,273)*(13,772)*(36,755)*(18,080)81,448*(175,733)*
Proceeds from issuing common stockyear only——0*381*——0*355*——0*
Share repurchases0*12,3016,134*0*21,804*46,92142,564*8,671*0*36,16538,715*0*
Net cash from financing activities(5,577)*(15,051)(8,273)*(2,722)*(23,046)*(49,337)(44,394)*(10,490)*(1,889)*(53,685)4,810*(4,321)*
Net change in cash2,478*15,584(31,052)*3,735*46,291*(17,005)(13,426)*20,187*7,024*(39,205)138,824*(133,687)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Aurinia Pharmaceuticals45,79283,69946,367*134.0M— 10-QSep 30, 2026
Harrow83,88970,661(9,755)*37.5M8.6 quarters 10-QJun 30, 2026
Novavax191,45856,698(72,807)*164.9M9.9 quarters 10-QJun 30, 2026
Neogen172,000222,80012,900218.3M— 10-QAug 31, 2026
Akebia Therapeutics155,54849,1283,525*277.1M— 10-QJun 30, 2026
Viridian Therapeutics164,986not reported(105,324)*113.3M9.3 quarters 10-QJun 30, 2026
Collegium Pharmaceutical129,467199,87871,323*32.6M— 10-QJun 30, 2026
Avadel Pharmaceuticals79,81377,46722,205*97.7M— 10-QSep 30, 2025
Ardelyx46,317127,6552,171*251.4M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.